Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL – OncLive
OncLive |
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL
OncLive Low disease burden prior to treatment with CD19-specific chimeric antigen receptor (CAR) T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia (ALL … |
